Week In Review: $2.5 Billion In Deals Including LianBio's Initial $719 Million In In-Licensings

LianBio, a new Princeton-Shanghai company, acquired China rights to two BridgeBio oncology assets in a $531.5 million agreement. BridgeBio will receive $26.5 million in upfront payments, plus up to $505 million in future milestones.